Proprietary AI analyst is now available

Oncoclínicas Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oncoclínicas and similar public comparables like Pihlajalinna, Atrys Health, Humana, Mater Dei and more.

Oncoclínicas Overview

About Oncoclínicas

Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology, and bone marrow transplantation, complementary care. The Group operates solely in the healthcare services segment, with an emphasis on oncology.


Founded

2010

HQ

Brazil

Employees

10.8K

Financials (LTM)

Revenue: $1B
EBITDA: $84M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Oncoclínicas Financials

Oncoclínicas reported last 12-month revenue of $1B and EBITDA of $84M.

In the same LTM period, Oncoclínicas generated $84M in EBITDA and had net loss of ($256M).

Revenue (LTM)


Oncoclínicas P&L

In the most recent fiscal year, Oncoclínicas reported revenue of $1B and EBITDA of $18M.

Oncoclínicas is unprofitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 2%, and net margin of (40%).

See analyst estimates for Oncoclínicas
LTMLast FY202320242025202620272028
Revenue$1B$1B$1B$1B$1B
Gross Profit-$352M$380M$406M$352M
Gross Margin-30%35%33%31%
EBITDA$84M$18M$221M$53M($439M)
EBITDA Margin7%2%20%4%(39%)
EBIT Margin(6%)(20%)13%(2%)(43%)
Net Profit($256M)($468M)$44M($127M)($714M)
Net Margin(22%)(40%)4%(10%)(63%)
Net Debt-$547M---

Financial data powered by Morningstar, Inc.

Oncoclínicas Stock Performance

Oncoclínicas has current market cap of $276M, and enterprise value of $1B.

Market Cap Evolution


Oncoclínicas' stock price is $0.25.

Oncoclínicas share price decreased by 7.5% in the last 30 days, and by 74.1% in the last year.

Oncoclínicas has an EPS (earnings per share) of $-0.42.

See more trading valuation data for Oncoclínicas
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$276M-2.7%-7.5%-20.2%-74.1%$-0.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Oncoclínicas Valuation Multiples

Oncoclínicas trades at 0.9x EV/Revenue multiple, and 12.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Oncoclínicas

EV / Revenue (LTM)


Oncoclínicas Financial Valuation Multiples

As of June 5, 2026, Oncoclínicas has market cap of $276M and EV of $1B.

Oncoclínicas has a P/E ratio of (1.1x).

LTMLast FY202320242025202620272028
EV/Revenue0.9x0.9x0.9x0.8x0.9x
EV/EBITDA12.0x56.4x4.6x18.9x(2.3x)
EV/EBIT(13.7x)(4.3x)6.9x(35.9x)(2.1x)
EV/Gross Profit-2.9x2.7x2.5x2.9x
P/E(1.1x)(0.6x)6.3x(2.2x)(0.4x)
EV/FCF-(17.9x)(14.1x)(12.8x)(17.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Oncoclínicas Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Oncoclínicas Margins & Growth Rates

Oncoclínicas grew revenue by 0% and EBITDA by 864% in the last fiscal year.

In the most recent fiscal year, Oncoclínicas reported gross margin of 30%, EBITDA margin of 2%, and net margin of (40%).

See estimated margins and future growth rates for Oncoclínicas

Oncoclínicas Margins

Last FY202420252026202720282029
Gross Margin30%33%31%-
EBITDA Margin2%4%(39%)15%
EBIT Margin(20%)(2%)(43%)12%
Net Margin(40%)(10%)(63%)2%
FCF Margin(5%)(6%)(5%)-

Oncoclínicas Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth0%13%(8%)4%
Gross Profit Growth-7%(13%)-
EBITDA Growth864%(76%)(922%)(139%)
EBIT Growth(161%)(119%)1628%(130%)
Net Profit Growth(106%)(389%)461%(104%)
FCF Growth-10%(28%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Oncoclínicas Operational KPIs

Oncoclínicas' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Oncoclínicas' Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oncoclínicas' Rule of X is 24% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Oncoclínicas
LTMLast FY202320242025202620272028
Rule of 4010%18%---
Bessemer Rule of X15%24%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue-23%21%22%24%
Opex to Revenue-72%22%35%74%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Oncoclínicas Competitors

Oncoclínicas competitors include Pihlajalinna, Atrys Health, Humana, Mater Dei, MediClin, Medica Sur, Auna, Goodwill Pharma, Clinica Las Condes and Monash IVF Group.

Most Oncoclínicas public comparables operate across Hospitals & Clinics.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pihlajalinna0.6x0.7x3.7x4.0x
Atrys Health2.8x2.7x19.6x17.8x
Humana0.6x0.6x5.7x5.7x
Mater Dei1.5x1.4x5.8x6.5x
MediClin0.6x0.5x3.9x3.7x
Medica Sur1.1x1.1x4.7x5.2x
Auna1.0x1.0x5.0x4.9x
Goodwill Pharma3.0x-11.2x-

This data is available for Pro users. Sign up to see all Oncoclínicas competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Oncoclínicas

When was Oncoclínicas founded?Oncoclínicas was founded in 2010.
Where is Oncoclínicas headquartered?Oncoclínicas is headquartered in Brazil.
How many employees does Oncoclínicas have?As of today, Oncoclínicas has over 10K employees.
Who is the CEO of Oncoclínicas?Oncoclínicas' CEO is Bruno Lemos Ferrari.
Is Oncoclínicas publicly listed?Yes, Oncoclínicas is a public company listed on B3.
What is the stock symbol of Oncoclínicas?Oncoclínicas trades under ONCO3 ticker.
When did Oncoclínicas go public?Oncoclínicas went public in 2021.
Who are competitors of Oncoclínicas?Oncoclínicas main competitors include Pihlajalinna, Atrys Health, Humana, Mater Dei, MediClin, Medica Sur, Auna, Goodwill Pharma, Clinica Las Condes, Monash IVF Group.
What is the current market cap of Oncoclínicas?Oncoclínicas' current market cap is $276M.
What is the current revenue of Oncoclínicas?Oncoclínicas' last 12 months revenue is $1B.
What is the current revenue growth of Oncoclínicas?Oncoclínicas revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of Oncoclínicas?Current revenue multiple of Oncoclínicas is 0.9x.
What is the current EBITDA of Oncoclínicas?Oncoclínicas' last 12 months EBITDA is $84M.
What is Oncoclínicas' EBITDA margin?Oncoclínicas' last 12 months EBITDA margin is 7%.
What is the current EV/EBITDA multiple of Oncoclínicas?Current EBITDA multiple of Oncoclínicas is 12.0x.
How many companies Oncoclínicas has acquired to date?Oncoclínicas hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Oncoclínicas has invested to date?Oncoclínicas hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Oncoclínicas

Lists including Oncoclínicas

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial